You are here

The results from the EAGLES* study mean you can recommend Champix varenicline for smokers looking to quit, with confidence.

Over 12 weeks of treatment with 12-week non-treatment follow up, in 8,144 smokers with or without a diagnosis of psychiatric disorders, EAGLES has shown that CHAMPIX (varenicline) has:

  • No significantly increased neuropsychiatric (NPS) safety risk vs. placebo, in smokers with or without a history of psychiatric disorders1
  • Significantly superior continuous abstinence rates vs. bupropion, NRT patch (NiQuitin® 21mg, with taper) and placebo at weeks 9-12 and 9-24 in both cohorts1

CHAMPIX was not associated with a significantly increased risk of NPS adverse events vs. placebo in smokers with or without a history of psychiatric disorders.†1.

Champix safety

CHAMPIX information for Smoking Cessation Advisors

PP-INT-GBR-0265
.  April 2021

For Smokers prescribed Champix (varenicline tartrate), Smoking Cessation Advisors and Health Professionals only.

These pages are not intended for members of the public. If you are one of the above please select 'Yes'. If you select 'No' you will be redirected to another webpage, which is provided as a resource.

PP-CHM-GBR-3741. June 2021. ©Pfizer Ltd. All rights reserved.

No Yes